Search
Cancer Clinical Trials
A listing of 283 Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 283
There are currently 283 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Pan Tumor Rollover Study
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Local Institution - 0220, Huntsville, Alabama +395 locations
Conditions: Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Recruiting
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Gender:
ALL
Ages:
Between 2 years and 99 years
Trial Updated:
07/31/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +2 locations
Conditions: Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Urology Centers of Alabama, PC, Homewood, Alabama +381 locations
Conditions: Cancer
Patient-Centered Assessment of Symptoms and Outcomes
Recruiting
Background:
The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different causes. Researchers think a therapy to treat one type of fatigue in one condition should be able to treat that type of fatigue in other conditions.
Objective:
To understand the types of fatigue.
Eligibility:
Adults 18 and older who have felt fatigue for more than a month, and non-fatigued adults
Design:
Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Recruiting
BACKGROUND
* This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols.
* It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Recruiting
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/31/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Recruiting
Background:
Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
Objective:
To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.
Eligibility:
People aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 gene... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Brain Tumor, Cancer
Rare Tumors and Cancer Predisposition in Individuals and Families
Recruiting
Background:
Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer.
Objective:
To understand how genes and environmental factors can cause tumors and related conditions.
Eligibility:
People of any age who:
Have tumors of an unusual type, pattern, or number
Have a family member with a history of cancer
Have been e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Cancer, Hereditary Neoplasms, Genetic Predisposition to Cancer, Environment
MAAT For Young Adult Cancer Survivors
Recruiting
The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measure... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/29/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana +2 locations
Conditions: Cancer
Dyadic Life Review Intervention for Older Patients With Advanced Cancer) and Their Caregivers
Recruiting
The purpose of this study is to test the feasibility of a pilot Randomized Controlled Trial (RCT) comparing Dyadic Life Review (DLR) intervention in older adults with advanced cancer and their caregivers to Care-as-Usual (CAU) group, which involves a referral to social work.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/29/2025
Locations: University of Rochester, Rochester, New York
Conditions: Cancer
Cancer Survivor Cardiomyopathy Detection
Recruiting
The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/28/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiovascular Diseases, Cancer
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Recruiting
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
1 - 12 of 283